Prenetics Global Limited (NASDAQ:PRE) Short Interest Update

Prenetics Global Limited (NASDAQ:PRE - Get Free Report) was the recipient of a large drop in short interest in May. As of May 15th, there was short interest totalling 23,600 shares, a drop of 20.8% from the April 30th total of 29,800 shares. Currently, 0.3% of the company's shares are short sold. Based on an average daily volume of 15,900 shares, the days-to-cover ratio is currently 1.5 days.

Institutional Investors Weigh In On Prenetics Global

A hedge fund recently bought a new stake in Prenetics Global stock. Quinn Opportunity Partners LLC purchased a new stake in Prenetics Global Limited (NASDAQ:PRE - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 12,339 shares of the company's stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned approximately 0.10% of Prenetics Global as of its most recent filing with the SEC. Institutional investors own 25.01% of the company's stock.

Prenetics Global Stock Performance

PRE traded down $0.32 during trading on Thursday, reaching $8.69. The company had a trading volume of 6,348 shares, compared to its average volume of 19,404. The firm's 50-day simple moving average is $5.77 and its 200 day simple moving average is $5.35. The company has a market cap of $106.00 million, a price-to-earnings ratio of -2.18 and a beta of 0.17. Prenetics Global has a 12-month low of $3.09 and a 12-month high of $11.99.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.